CAMK2G and myocardial infarction: (2) In rats with myocardial infarction, WXKL treatment can significantly reduce the expression of CaMKII, p-CaMKII (Thr-286), and PLB, while significantly increasing the expression of RyR2, p-PLB (Thr-17), and FKBP12.6.